516 related articles for article (PubMed ID: 18242159)
21. The Ser252Trp fibroblast growth factor receptor-2 (FGFR-2) mutation induces PKC-independent downregulation of FGFR-2 associated with premature calvaria osteoblast differentiation.
Lemonnier J; Delannoy P; Hott M; Lomri A; Modrowski D; Marie PJ
Exp Cell Res; 2000 Apr; 256(1):158-67. PubMed ID: 10739663
[TBL] [Abstract][Full Text] [Related]
22. Aberrantly activated Wnt/β-catenin pathway co-receptors LRP5 and LRP6 regulate osteoblast differentiation in the developing coronal sutures of an Apert syndrome (Fgfr2
Min Swe NM; Kobayashi Y; Kamimoto H; Moriyama K
Dev Dyn; 2021 Mar; 250(3):465-476. PubMed ID: 32822074
[TBL] [Abstract][Full Text] [Related]
23. Inhibited Wnt signaling causes age-dependent abnormalities in the bone matrix mineralization in the Apert syndrome FGFR2(S252W/+) mice.
Zhang L; Chen P; Chen L; Weng T; Zhang S; Zhou X; Zhang B; Liu L
PLoS One; 2015; 10(2):e112716. PubMed ID: 25693202
[TBL] [Abstract][Full Text] [Related]
24. S252W mutation in Indian patients of Apert syndrome.
Girisha KM; Phadke SR; Khan F; Agrawal S
Indian Pediatr; 2006 Aug; 43(8):733-5. PubMed ID: 16951439
[TBL] [Abstract][Full Text] [Related]
25. FGF/FGFR signaling coordinates skull development by modulating magnitude of morphological integration: evidence from Apert syndrome mouse models.
Martínez-Abadías N; Heuzé Y; Wang Y; Jabs EW; Aldridge K; Richtsmeier JT
PLoS One; 2011; 6(10):e26425. PubMed ID: 22053191
[TBL] [Abstract][Full Text] [Related]
26. Excessive osteoclast activation by osteoblast paracrine factor RANKL is a major cause of the abnormal long bone phenotype in Apert syndrome model mice.
Shin HR; Kim BS; Kim HJ; Yoon H; Kim WJ; Choi JY; Ryoo HM
J Cell Physiol; 2022 Apr; 237(4):2155-2168. PubMed ID: 35048384
[TBL] [Abstract][Full Text] [Related]
27. Apert syndrome results from localized mutations of FGFR2 and is allelic with Crouzon syndrome.
Wilkie AO; Slaney SF; Oldridge M; Poole MD; Ashworth GJ; Hockley AD; Hayward RD; David DJ; Pulleyn LJ; Rutland P
Nat Genet; 1995 Feb; 9(2):165-72. PubMed ID: 7719344
[TBL] [Abstract][Full Text] [Related]
28. Novel molecular pathways elicited by mutant FGFR2 may account for brain abnormalities in Apert syndrome.
Yeh E; Fanganiello RD; Sunaga DY; Zhou X; Holmes G; Rocha KM; Alonso N; Matushita H; Wang Y; Jabs EW; Passos-Bueno MR
PLoS One; 2013; 8(4):e60439. PubMed ID: 23593218
[TBL] [Abstract][Full Text] [Related]
29. Identification and characterization of an inhibitory fibroblast growth factor receptor 2 (FGFR2) molecule, up-regulated in an Apert Syndrome mouse model.
Wheldon LM; Khodabukus N; Patey SJ; Smith TG; Heath JK; Hajihosseini MK
Biochem J; 2011 May; 436(1):71-81. PubMed ID: 21355848
[TBL] [Abstract][Full Text] [Related]
30. Mesodermal expression of Fgfr2S252W is necessary and sufficient to induce craniosynostosis in a mouse model of Apert syndrome.
Holmes G; Basilico C
Dev Biol; 2012 Aug; 368(2):283-93. PubMed ID: 22664175
[TBL] [Abstract][Full Text] [Related]
31. PIN1 Attenuation Improves Midface Hypoplasia in a Mouse Model of Apert Syndrome.
Kim B; Shin H; Kim W; Kim H; Cho Y; Yoon H; Baek J; Woo K; Lee Y; Ryoo H
J Dent Res; 2020 Feb; 99(2):223-232. PubMed ID: 31869252
[TBL] [Abstract][Full Text] [Related]
32. Role of N-cadherin and protein kinase C in osteoblast gene activation induced by the S252W fibroblast growth factor receptor 2 mutation in Apert craniosynostosis.
Lemonnier J; Haÿ E; Delannoy P; Lomri A; Modrowski D; Caverzasio J; Marie PJ
J Bone Miner Res; 2001 May; 16(5):832-45. PubMed ID: 11341328
[TBL] [Abstract][Full Text] [Related]
33. Morphological comparison of the craniofacial phenotypes of mouse models expressing the Apert FGFR2 S252W mutation in neural crest- or mesoderm-derived tissues.
Heuzé Y; Singh N; Basilico C; Jabs EW; Holmes G; Richtsmeier JT
Bone; 2014 Jun; 63():101-9. PubMed ID: 24632501
[TBL] [Abstract][Full Text] [Related]
34. Effects of FGFR Signaling on Cell Proliferation and Differentiation of Apert Dental Cells.
Lu C; Huguley S; Cui C; Cabaniss LB; Waite PD; Sarver DM; Mamaeva OA; MacDougall M
Cells Tissues Organs; 2016; 201(1):26-37. PubMed ID: 26613250
[TBL] [Abstract][Full Text] [Related]
35. RNA interference and inhibition of MEK-ERK signaling prevent abnormal skeletal phenotypes in a mouse model of craniosynostosis.
Shukla V; Coumoul X; Wang RH; Kim HS; Deng CX
Nat Genet; 2007 Sep; 39(9):1145-50. PubMed ID: 17694057
[TBL] [Abstract][Full Text] [Related]
36. Ocular abnormalities in Apert syndrome: genotype/phenotype correlations with fibroblast growth factor receptor type 2 mutations.
Jadico SK; Young DA; Huebner A; Edmond JC; Pollock AN; McDonald-McGinn DM; Li YJ; Zackai EH; Young TL
J AAPOS; 2006 Dec; 10(6):521-7. PubMed ID: 17189145
[TBL] [Abstract][Full Text] [Related]
37. Sequence analysis of fibroblast growth factor receptor 2 ( FGFR2 ) in Japanese patients with craniosynostosis.
Sakai N; Tokunaga K; Yamazaki Y; Shida H; Sakata Y; Susami T; Nakakita N; Takato T; Uchinuma E
J Craniofac Surg; 2001 Nov; 12(6):580-5. PubMed ID: 11711827
[TBL] [Abstract][Full Text] [Related]
38. Fibroblast growth factor receptor 2 promotes osteogenic differentiation in mesenchymal cells via ERK1/2 and protein kinase C signaling.
Miraoui H; Oudina K; Petite H; Tanimoto Y; Moriyama K; Marie PJ
J Biol Chem; 2009 Feb; 284(8):4897-904. PubMed ID: 19117954
[TBL] [Abstract][Full Text] [Related]
39. Therapeutic effect of nanogel-based delivery of soluble FGFR2 with S252W mutation on craniosynostosis.
Yokota M; Kobayashi Y; Morita J; Suzuki H; Hashimoto Y; Sasaki Y; Akiyoshi K; Moriyama K
PLoS One; 2014; 9(7):e101693. PubMed ID: 25003957
[TBL] [Abstract][Full Text] [Related]
40. The Fgfr2(S252W/+) mutation in mice retards mandible formation and reduces bone mass as in human Apert syndrome.
Zhou X; Pu D; Liu R; Li X; Wen X; Zhang L; Chen L; Deng M; Liu L
Am J Med Genet A; 2013 May; 161A(5):983-92. PubMed ID: 23495007
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
